Novo Nordisk AS (OCSE:NOVO B)
kr 757.3 9.7 (1.3%) Market Cap: 3.36 Til Enterprise Value: 3.35 Til PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 97/100

Q4 2023 Novo Nordisk A/S Earnings Call Transcript

Jan 31, 2024 / 12:00PM GMT
Release Date Price: kr774.8 (+3.56%)
Operator

Good day and thank you for standing by. Welcome to the Q4 2023 Novo Nordisk Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Daniel Bohsen, CVP and Investor Relations. Please go ahead.

Daniel Bohsen;S;CVP;Head of IR
Novo Nordisk A

/-&

Welcome to this Novo Nordisk Earnings Call for the full year of 2023 and the outlook for 2024. My name is Daniel Muusmann Bohsen and I'm the Head of Investor Relations at Novo Nordisk.

With me today I have CEO of Novo Nordisk, Lars Fruergaard Jorgensen; Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla Sylvest; Executive Vice President and Head of North America Operations, Doug Langa; Executive Vice President and Head of Development, Martin Holst Lange; and finally, Chief Financial Officer, Karsten Munk Knudsen.

All speakers will be available for the Q&A session. Today's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot